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measure the expression of MMP-2 and MMP-9 in lung tissues of PSP patients. The results were
further correlated with clinicopathological parameters and recurrence rates using chi-square
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pneumothorax, Kaohsiung Journal ofby univariate and multivariable Cox regression model. IHC data revealed that MMP-2 and MMP-
9 staining was predominantly observed in type II pneumocytes of patients with PSP. We found
that MMP-2 and MMP-9 expression in PSP, especially male PSP patients, was significantly corre-
lated with recurrence. In the univariate and multivariate analyses, MMP-2 and MMP-9 were sta-
tistically significant risk factors for overall recurrence in PSP patients. Therefore, high
expression levels of MMP-2 and MMP-9 in type II pneumocytes show a positive correlation with
PSP recurrence risk. Further studies are needed to validate whether reduction of MMP-2 and
MMP-9 expression may be a promising way for decreasing the risk of PSP recurrence in the
future.
Copyright ª 2016, Kaohsiung Medical University. Published by Elsevier Taiwan LLC. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/
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Primary spontaneous pneumothorax (PSP) is an important
health problem, mostly occurs in young males, and is
encountered in clinical practice [1]. It has an annual inci-
dence of 18e28/100,000 in males and 1.2e6/100,000 in
females [2]. PSP occurs without trauma or obvious precip-
itating cause and arises in persons without clinically
apparent lung diseases. The average rate of ipsilateral
recurrence of PSP is 30%, with a range of 16e52%, and the
incidence of contralateral recurrence is around 15% after
first episode of PSP [3,4].
PSP is caused by chronic destruction of subpleural
alveolar structures because of hypoxia, oxidative stress,
and chronic inflammation [5,6]. PSP is associated with the
degradation of elastic fibers and is mediated through
infiltration of proinflammatory mediators secreted by type
II pneumocytes [7]. The elastolysis in lung disease is
caused by an imbalance of proteases and antiproteases
[8,9].
Matrix metalloproteinases (MMPs) comprise a family of
zinc-dependent enzymes and are classified into several
subgroups: collagenases, gelatinases, stromelysins, elas-
tases, and membrane-type MMPs [10,11]. Although MMPs
play a crucial physiological role in wound healing, tissue
remodeling, and angiogenesis, their overexpression is
connected to some pulmonary diseases [12,13]. PSP is
caused by the fracture of the pulmonary parenchyma or
visceral pleura, which is related to the weakening of sub-
pleural lung tissue. Recently, MMP-2 and MMP-9 have been
marked as being critical for the clinical pathology of lung
diseases [14e16].
Type II pneumocyte hyperplasia was reported to be
associated with reactive epithelial change in pneumo-
thorax [17]. However, the expression of MMP-2 and MMP-9
in type II pneumocytes of PSP patients and their relation-
ship to PSP recurrence remain unknown. In the current
study, we examined MMP-2 and MMP-9 expression levels in
type II pneumocytes of both lung tissue resections and
surrounding normal tissue resections by immunohisto-
chemical (IHC) staining. Their association with the clinical
variables was assessed as to whether MMP-2 and MMP-9
expression levels may be clinical factors involved in PSP
recurrence.ang Y-F, et al., Association of MMP
Medical Sciences (2016), http://Materials and methods
Participant samples
From January 2012 to December 2013, we retrospectively
reviewed the clinical data of 91 PSP patients who under-
went surgery at the Division of Thoracic Surgery, Depart-
ment of Surgery, Kaohsiung Medical University Hospital
(Kaohsiung, Taiwan). They received surgical treatment
owing to recurrence, persistent air leak (for 5 days), or
patient preference. PSP patients included in this study were
diagnosed by chest radiography and computed tomography
(CT) scan as well as their age (40 years). Some patients
were excluded because of secondary pneumothorax, trau-
matic or iatrogenic pneumothorax, lung disease (i.e.,
asthma, pneumonia, chronic obstructive pulmonary dis-
ease, tumor), or lung surgery (i.e., wedge resection of the
lung, lobectomy). The recurrence group consisted of pa-
tients with radiological proof of relapse of pneumothorax
after the first episode of PSP, and their specimens and
adjacent normal lung tissues were collected while they
were undergoing surgery. The nonrecurrence group con-
sisted of persons who underwent surgery during their first
admittance with PSP and had no recurrence during a 2-year
follow-up period. All resections were carried out for IHC
staining. The age, sex, body mass index (BMI, kg/m2),
smoking status, and side of pneumothorax were recorded.
The study was approved by the Kaohsiung Medical University
Hospital Institutional Review Board (KMUH-IRB-20130268),
and informed consent was obtained from all patients.
Operative technique
The operative technique for needlescopic video-assisted
thoracoscopic surgery blebectomy has been described
previously [18].
IHC staining
IHC staining for MMP-2 and MMP-9 was performed on a
Bond-Max autostainer (Leica Microsystems, Bannockburn,
IL, USA) as described previously [19]. In brief, resections
were incubated with MMP-2 (1:200; Abgent, San Diego, CA,-2 and MMP-9 expression with recurrences in primary spontaneous
dx.doi.org/10.1016/j.kjms.2016.10.007
Table 1 Clinical characteristics of patients with primary
spontaneous pneumothorax.
Characteristics n Z 91
Age (y) 21.0  5.4
Sex
Male 78 (85.7)
Female 13 (14.3)
Height (cm) 172.6  7.5
Body weight (kg) 56.3  8.7
BMI (kg/m2) 18.8  2.2
Smoking
Yes 17 (18.7)
No 74 (81.3)
Side involved
Unilateral 65 (71.4)
Bilateral 26 (28.6)
Recurrence
Yes 48 (52.7)
No 43 (47.3)
Data are presented as the mean  SD and n (%).
BMI Z body mass index; SD Z standard deviation.
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development was performed with 3,30-diaminobenzidine
tetrahydrochloride. Slides were counterstained with he-
matoxylin, and images of IHC-stained sections were
captured by a Nikon Eclipse Ti microscope (Nikon, Tokyo,
Japan). Negative control was performed in the same way
except for the addition with MMP-2 and MMP-9 antibodies.
Slide evaluation
Analysis of MMP-2 and MMP-9 staining results were scored
according to the staining intensity of positively stained
cells, determined by two independent observers under the
same condition. The staining intensity was scored as fol-
lows: 0 Z absent; 1 Z weak; 2 Z moderate; 3 Z strong.
Four visual fields were observed randomly per slide, and the
average score of stained cells in the four fields was taken
for each PSP specimen. For statistical analysis, scores 0 and
1 were categorized as low expression, whereas scores 2 and
3 were categorized as high expression.
Statistical analysis
All statistical analyses were conducted using the SPSS 20.0
statistical package for PC (SPSS, Chicago, IL, USA). Corre-
lations between low-expression and high-expression groups
of MMP-2 or MMP-9 with age, sex, BMI, recurrence, smoking
status, and side of pneumothorax were analyzed using the
chi-square test or Fisher’s exact test. Hazard ratio (HR) and
95% confidence interval (CI) from univariate and multivar-
iable analyses using Cox proportional hazards regression
models were performed to calculate the correlations be-
tween overall recurrence and clinical variables. All p values
less than 0.05 were considered statistically significant.
Results
Expression levels of MMP-2 and MMP-9 in type II
pneumocytes of patients with PSP
A total of 91 patients, 78 males and 13 females, with PSP
were enrolled in the present study. Clinical variables (age,
sex, BMI, smoking status, lesion location, and recurrence)
of the patients with PSP are summarized in Table 1.
Representative features for MMP-2 and MMP-9 expression in
type II pneumocytes are shown in Figure 1. Differences in
MMP-2 and MMP-9 staining between the PSP tissues and the
adjacent normal lung tissues were predominantly observed.
MMP-2 and MMP-9 expression in type II pneumocytes are
consistently negative in the adjacent normal lung tissues
from PSP patients (n Z 15). Human breast cancer tissues
were used as the positive control to assess the levels of
MMP-2 and MMP-9 [20,21] and are depicted in Figure 1.
Comparisons of MMP-2 and MMP-9 expression levels
in PSP patients with clinical variables
MMP-2 and MMP-9 expression levels in PSP patients were
associated with clinical characteristics including age, sex,
BMI, recurrence, smoking status, and side involved (TablePlease cite this article in press as: Huang Y-F, et al., Association of MMP
pneumothorax, Kaohsiung Journal of Medical Sciences (2016), http://2). High MMP-2 expression in PSP patients was signifi-
cantly correlated with increased recurrence risk
(pZ 0.004), whereas high MMP-9 expression was correlated
with increased recurrence (pZ 0.009) and sex (pZ 0.008)
(Table 2). The information for age, BMI, smoking status, and
side involved in high expression and low expression of MMP-
2 and MMP-9 groups were not significantly different (Table
2). Further analysis in male PSP patients revealed
increased disease recurrence in high MMP-2 groups
(pZ 0.011) and in high MMP-9 groups (pZ 0.039) (Table 3).
Correlation between MMP-2 and MMP-9 expression
levels and overall recurrence in PSP patients
To study the association between MMP-2 and MMP-9
expression as well as clinical variables with overall recur-
rence, univariate and multivariable Cox regression analyses
are shown in Table 4. In the univariate analysis, the factors
significantly associated with overall recurrence included
age (HR Z 0.53, 95% CI Z 0.28 e 0.97, p Z 0.041), MMP-2
(HR Z 2.19, 95% CI Z 1.21 e 3.96, p Z 0.009), and MMP-9
(HRZ 2.58, 95% CIZ 1.27 e 5.23, pZ 0.009) (Table 4). In
the multivariate analyses, MMP-2 (HR Z 2.00, 95%
CI Z 1.06 e 3.78, p Z 0.032) and MMP-9 (HR Z 2.86, 95%
CI Z 1.22 e 6.70, p Z 0.016) showed significant associa-
tions with overall recurrence (Table 4).
Discussion
The pathogenesis of PSP remains unknown and may arise
from airway inflammation, pulmonary fibrosis, genetic
factors, bronchial anomaly, intrathoracic pressure change,
and low BMI [2,22e24]. One of the key approaches in the
management of PSP is to prevent recurrence. Bullectomy is
an effective way to decrease the recurrence risk [25].
Casali et al. [26] demonstrated that first episode of PSP-2 and MMP-9 expression with recurrences in primary spontaneous
dx.doi.org/10.1016/j.kjms.2016.10.007
Figure 1. Immunohistochemical (IHC) staining for (A) MMP-2 and (B) MMP-9 in type II pneumocytes of PSP. PSP lung tissue slides
were stained using methods described in Materials and methods. Staining was scored according to the staining intensity in four
quantitative categories (0 Z absent staining; 1 Z weak staining; 2 Z moderate staining; 3 Z strong staining). The expression of
MMP-2 and MMP-9 in the matched adjacent normal lung tissues and negative control are also shown. The representative photo-
graphs are shown with 400 magnification. MMP-2 Z matrix metalloproteinase-2; MMP-9 Z matrix metalloproteinase-9;
PSP Z primary spontaneous pneumothorax.
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bullae detected on pulmonary high-resolution CT. Another
study reported that greater CT-based lung dystrophy
severity scores resulted in significantly higher PSP recur-
rence rates [27]. However, previous study indicated that
the dystrophic score was not statistically associated with
the risk of recurrence [28]. Therefore, the risk factors
correlated with PSP recurrence are still unclear. In this
study, our significant findings showed that MMP-2 and MMP-
9 expression in PSP tissues were adversely associated with
the recurrence risk.
In lung diseases, the sources of MMP-2 and MMP-9 are
bronchial epithelial cells, type II pneumocytes, fibroblasts,
and alveolar macrophages [16,29]. However, there are far
fewer reports studying MMP-2 and MMP-9 expression in PSP
lung tissues and their association with clinical variables of
PSP patients. Chen et al. [30] reported that upregulation of
MMP-2, MMP-9, MMP-7, and TIMP-2 was detected in PSP
patients but lacked correlations with clinicalPlease cite this article in press as: Huang Y-F, et al., Association of MMP
pneumothorax, Kaohsiung Journal of Medical Sciences (2016), http://characteristics. In this study, we demonstrated that in PSP
tissues, MMP-2 and MMP-9 was expressed in type II pneu-
mocytes (Figure 1), the cell type that is essential for
maintaining alveolar stability and reconstructing the intact
alveolus. The significantly increased MMP-2 and MMP-9 ex-
pressions in PSP tissues were independent risk factors for
overall recurrence in PSP (Table 4). To the best of our
knowledge, this study is the only study to examine the in-
fluence of MMP-2 and MMP-9 expression in type II pneu-
mocytes on overall recurrence of PSP.
In the present study, we found that most patients with
PSP were male (Table 1). The difference was significant in
the percentage of male and female patients in MMP-9
expression group (Table 2). Further analysis in male PSP
patients showed that recurrence risk was significantly
different between low expression and high expression of
MMP-2 or MMP-9 groups (Table 3). These data indicated that
male sex is still a risk factor for PSP and subsequent
recurrence, especially among male PSP patients with high-2 and MMP-9 expression with recurrences in primary spontaneous
dx.doi.org/10.1016/j.kjms.2016.10.007
Table 2 Clinical characteristics of pneumothorax patients with MMP-2 and MMP-9 expression.
Variables Item Patients, n (%) MMP-2 MMP-9
Low High p Low High p
No. % No. % No. % No. %
Age (y) 20 53 (58.2) 29 59.2 24 57.1 0.844a 14 46.7 39 63.9 0.116a
>20 38 (41.8) 20 40.8 18 42.9 16 53.3 22 36.1
Sex Male 78 (85.7) 43 87.8 35 83.3 0.548a 21 70.0 57 93.4 0.008b
Female 13 (14.3) 6 12.2 7 16.7 9 30.0 4 6.6
BMI <18 36 (39.6) 19 38.8 17 40.5 0.869a 10 33.3 26 42.6 0.394a
18 55 (60.4) 30 61.2 25 59.5 20 60.7 35 57.4
Recurrence No 43 (47.3) 30 61.2 13 31.0 0.004a 20 66.7 23 37.7 0.009a
Yes 48 (52.7) 19 38.8 29 69.0 10 33.3 38 62.3
Smoking status No 74 (81.3) 38 77.6 36 85.7 0.319a 24 80.0 50 82.0 0.821a
Yes 17 (18.7) 11 22.4 6 14.3 6 20.0 11 18.0
Side involved Unilateral 65 (71.4) 32 65.3 33 78.6 0.163a 23 76.7 42 68.9 0.438a
Bilateral 26 (28.6) 17 34.7 9 21.4 7 23.3 19 31.1
BMI Z body mass index; MMP-2 Z matrix metalloproteinase-2; MMP-9 Z matrix metalloproteinase-9.
a The p value was calculated using chi-square test.
b The p value was calculated using Fisher’s exact test.
Table 3 Clinical characteristics of male pneumothorax patients with MMP-2 and MMP-9 expression.
Variables Item Patients n (%) MMP-2 MMP-9
Low High p Low High p
No. % No. % No. % No. %
Age (y) 20 49 (62.8) 27 62.8 22 62.9 0.995a 11 52.4 38 66.7 0.247a
>20 29 (37.2) 16 37.2 13 37.1 10 47.6 19 33.3
BMI <18 31 (39.7) 17 39.5 14 40.0 0.967a 8 38.1 23 40.4 0.857a
18 47 (60.3) 26 60.5 21 60.0 13 61.9 34 59.6
Recurrence No 37 (47.4) 26 60.5 11 31.4 0.011a 14 66.7 23 40.4 0.039a
Yes 41 (52.6) 17 39.5 24 68.6 7 33.3 34 59.6
Smoking status No 63 (80.8) 33 76.7 30 85.7 0.317a 17 81.0 46 80.7 >0.999b
Yes 15 (19.2) 10 23.3 5 14.3 4 19.0 11 19.3
Side involved Unilateral 55 (70.5) 28 65.1 27 77.1 0.247a 16 76.2 39 68.4 0.504a
Bilateral 23 (29.5) 15 34.9 8 22.9 5 23.8 18 31.6
BMI Z body mass index; MMP-2 Z matrix metalloproteinase-2; MMP-9 Z matrix metalloproteinase-9.
a The p value was calculated using chi-square test.
b The p value was calculated using Fisher’s exact test.
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higher number of recurrent cases was found in the present
study, with 52.7% of PSP patients (48 out of 91) having
recurrence after the first episode of PSP. The reason for the
higher number of recurrent cases was that most patients
presenting with a PSP recurrence and primarily treated at
nearby local hospitals were referred to our medical center
for surgical therapy.
Some factors, such as age or smoking, have been found
to be involved in recurrent spontaneous pneumothorax
[4,31]. In the univariate analysis, the HR of overall recur-
rence in the age > 20 years group was 0.53 and that in the
age  20 years group was 1.0 (Table 4), revealing that
recurrence predominantly affects young patients with PSP.
Exposure to cigarette smoking causes emphysema-like
symptoms, and is associated with oxidative DNA adduct
formation, apoptosis, and bronchiolar inflammationPlease cite this article in press as: Huang Y-F, et al., Association of MMP
pneumothorax, Kaohsiung Journal of Medical Sciences (2016), http://[32e34]. However, our data showed no significant correla-
tion between smoking status and MMP-2 or MMP-9 expres-
sion in PSP patients (Table 2). The lack of association in this
study may be attributable to the small number of smokers
in the PSP patient sample (17 out of 91). Therefore, eval-
uation of associated risk factors for recurrence in young PSP
patients, including the analysis of MMP-2 and MMP-9
expression, may provide useful information for clinicians
in medical practice. Further large-scale clinical studies are
needed to enforce the findings in the present study.
In conclusion, we observed a significant association be-
tween PSP tissue MMP-2 and MMP-9 expression and the
recurrence risk. High expression of MMP-2 and MMP-9 was
observed to be independently associated with overall
recurrence. These data suggest that inhibition of MMP-2
and MMP-9 may be a potential way for reducing PSP
recurrence risk.-2 and MMP-9 expression with recurrences in primary spontaneous
dx.doi.org/10.1016/j.kjms.2016.10.007
Table 4 Univariate and multivariable analysis for overall recurrence in pneumothorax patients.
Variables Item Univariate Multivariable
HR 95% CI p HR 95% CI p
Age (y) >20 0.53 (0.28, 0.97) 0.041* 0.55 (0.26, 1.14) 0.107
20 1.00 1.00
Sex Female 1.27 (0.53, 3.00) 0.594 2.61 (0.94, 7.31) 0.067
Male 1.00 1.00
BMI 18 0.98 (0.54, 1.76) 0.935 1.15 (0.59, 2.23) 0.679
<18 1.00 1.00
Smoking status Yes 0.50 (0.21, 1.18) 0.115 0.69 (0.27, 1.76) 0.441
No 1.00 1.00
Side involved Unilateral 1.19 (0.62, 2.29) 0.607 1.35 (0.68, 2.69) 0.393
Bilateral 1.00 1.00
MMP-2 High 2.19 (1.21, 3.96) 0.009* 2.00 (1.06, 3.78) 0.032*
Low 1.00 1.00
MMP-9 High 2.58 (1.27, 5.23) 0.009* 2.86 (1.22, 6.70) 0.016*
Low 1.00 1.00
*p < 0.05, statistically significant.
BMI Z body mass index; CI Z confidence interval; HR Z hazard ratio; MMP-2 Z matrix metalloproteinase-2; MMP-9 Z matrix metal-
loproteinase-9.
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